BioLineRx is trading at $2.44, down 5.79%, in a risk-off session amid geopolitical tensions and rising oil prices; broader market weakness may contribute but does not establish a direct cause.
- The Dow is down 0.65%.
- No September 28 company announcement appears in BioLineRx’s press-release listings; its latest listed release is dated September 10.
- Recent GLIX1 presentation news and August financing are earlier developments, not confirmed catalysts for the decline.